{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:39:41Z","timestamp":1790710781201,"version":"4.1.0"},"reference-count":99,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T00:00:00Z","timestamp":1659571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Oncogenic fusion genes have emerged as successful targets in several malignancies, such as chronic myeloid leukemia and lung cancer. Fusion of the fibroblast growth receptor 3 and the transforming acidic coiled coil containing protein\u2014FGFR3-TACC3 fusion\u2014is prevalent in 3\u20134% of human glioblastoma. The fusion protein leads to the constitutively activated kinase signaling of FGFR3 and thereby promotes cell proliferation and tumor progression. The subgroup of FGFR3-TACC3 fusion-positive glioblastomas presents with recurrent clinical and histomolecular characteristics, defining a distinctive subtype of IDH-wildtype glioblastoma. This review aims to provide an overview of the available literature on FGFR3-TACC3 fusions in glioblastoma and possible implications for actual clinical practice.<\/jats:p>","DOI":"10.3390\/ijms23158675","type":"journal-article","created":{"date-parts":[[2022,8,4]],"date-time":"2022-08-04T21:52:48Z","timestamp":1659649968000},"page":"8675","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["FGFR3-TACCs3 Fusions and Their Clinical Relevance in Human Glioblastoma"],"prefix":"10.3390","volume":"23","author":[{"given":"Hanna","family":"G\u00f6tt","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, University Hospital Giessen, 35398 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eberhard","family":"Uhl","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, University Hospital Giessen, 35398 Giessen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1182\/asheducation-2018.1.161","article-title":"The argument for using imatinib in CML","volume":"2018","author":"Claudiani","year":"2018","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Gristina, V., La Mantia, M., Iacono, F., Galvano, A., Russo, A., and Bazan, V. (2020). The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer. Pharmaceuticals, 13.","DOI":"10.3390\/ph13120474"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Elsayed, M., and Christopoulos, P. (2021). Therapeutic Sequencing in ALK+ NSCLC. Pharmaceuticals, 14.","DOI":"10.3390\/ph14020080"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/S0140-6736(18)31791-4","article-title":"Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG\/NOA-09): A randomised, open-label, phase 3 trial","volume":"393","author":"Herrlinger","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1001\/jama.2015.16669","article-title":"Maintenance Therapy with Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial","volume":"314","author":"Stupp","year":"2015","journal-title":"JAMA"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1001\/jama.2017.18718","article-title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients with Glioblastoma: A Randomized Clinical Trial","volume":"318","author":"Stupp","year":"2017","journal-title":"JAMA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1126\/science.1220834","article-title":"Transforming fusions of FGFR and TACC genes in human glioblastoma","volume":"337","author":"Singh","year":"2012","journal-title":"Science"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/noaa200","article-title":"CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013\u20132017","volume":"22","author":"Ostrom","year":"2020","journal-title":"Neuro-oncology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ncpneuro0289","article-title":"Epidemiology and molecular pathology of glioma","volume":"2","author":"Schwartzbaum","year":"2006","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","article-title":"cIMPACT-NOW update 6: New entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00401-018-1913-0","article-title":"cIMPACT-NOW update 3: Recommended diagnostic criteria for \u201cDiffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV\u201d","volume":"136","author":"Brat","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12094-016-1497-x","article-title":"Survival in glioblastoma: A review on the impact of treatment modalities","volume":"18","year":"2016","journal-title":"Clin. Transl. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1056\/NEJMoa1707358","article-title":"Lomustine and Bevacizumab in Progressive Glioblastoma","volume":"377","author":"Wick","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.jmb.2004.04.031","article-title":"Towards a resolution of the stoichiometry of the fibroblast growth factor (FGF)-FGF receptor-heparin complex","volume":"339","author":"Harmer","year":"2004","journal-title":"J. Mol. Biol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/path.4297","article-title":"Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours","volume":"232","author":"Parker","year":"2014","journal-title":"J. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1073\/pnas.89.1.246","article-title":"Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene","volume":"89","author":"Miki","year":"1992","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.molcel.2009.01.025","article-title":"ESRP1 and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing","volume":"33","author":"Warzecha","year":"2009","journal-title":"Mol. Cell"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Latko, M., Czyrek, A., Por\u0119bska, N., Kuci\u0144ska, M., Otlewski, J., Zakrzewska, M., and Opali\u0144ski, \u0141. (2019). Cross-Talk between Fibroblast Growth Factor Receptors and Other Cell Surface Proteins. Cells, 8.","DOI":"10.3390\/cells8050455"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1186\/s12964-019-0371-1","article-title":"Differential regulation of fibroblast growth factor receptor 1 trafficking and function by extracellular galectins","volume":"17","author":"Lampart","year":"2019","journal-title":"Cell Commun. Signal."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Jimenez-Pascual, A., and Siebzehnrubl, F.A. (2019). Fibroblast Growth Factor Receptor Functions in Glioblastoma. Cells, 8.","DOI":"10.3390\/cells8070715"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"55924","DOI":"10.18632\/oncotarget.10482","article-title":"FGFR3-TACC3 fusion in solid tumors: Mini review","volume":"7","author":"Costa","year":"2016","journal-title":"Oncotarget"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1073\/pnas.0914157107","article-title":"Asymmetric receptor contact is required for tyrosine autophosphorylation of fibroblast growth factor receptor in living cells","volume":"107","author":"Bae","year":"2010","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Ferguson, H.R., Smith, M.P., and Francavilla, C. (2021). Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling. Cells, 10.","DOI":"10.3390\/cells10051201"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.tips.2012.07.001","article-title":"Anticancer molecules targeting fibroblast growth factor receptors","volume":"33","author":"Liang","year":"2012","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_31","first-page":"855","article-title":"The tumorigenic FGFR3-TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker","year":"2013","journal-title":"J. Clin. Invest."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6127","DOI":"10.1158\/0008-5472.CAN-04-1207","article-title":"The ras\/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer","volume":"64","author":"Lo","year":"2004","journal-title":"Cancer Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1074\/jbc.M108368200","article-title":"Sprouty2 inhibits the Ras\/MAP kinase pathway by inhibiting the activation of Raf","volume":"277","author":"Yusoff","year":"2002","journal-title":"J. Biol. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","article-title":"COSMIC: Somatic cancer genetics at high-resolution","volume":"45","author":"Forbes","year":"2017","journal-title":"Nucleic. Acids Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1158\/0008-5472.CAN-15-2058","article-title":"FGFR1 Induces Glioblastoma Radioresistance through the PLC\u03b3\/Hif1\u03b1 Pathway","volume":"76","author":"Delmas","year":"2016","journal-title":"Cancer Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1158\/2159-8290.CD-18-1308","article-title":"ADAMDEC1 Maintains a Growth Factor Signaling Loop in Cancer Stem Cells","volume":"9","author":"Hale","year":"2019","journal-title":"Cancer Discov."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"84587","DOI":"10.18632\/oncotarget.13139","article-title":"FGFR3, as a receptor tyrosine kinase, is associated with differentiated biological functions and improved survival of glioma patients","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR Landscape in Cancer: Analysis of 4,853 Tumors by Next-Generation Sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_39","first-page":"3893","article-title":"Comprehensive identification of FGFR1-4 alterations in 5 557 Chinese patients with solid tumors by next-generation sequencing","volume":"11","author":"Gu","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.1038\/ncomms5846","article-title":"The landscape of kinase fusions in cancer","volume":"5","author":"Stransky","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.18632\/oncotarget.3212","article-title":"Comprehensive analysis of targetable oncogenic mutations in chinese cervical cancers","volume":"6","author":"Xiang","year":"2015","journal-title":"Oncotarget"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4107","DOI":"10.1158\/1078-0432.CCR-14-0284","article-title":"FGFR1\/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer","volume":"20","author":"Wang","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"6551","DOI":"10.1158\/1078-0432.CCR-14-1337","article-title":"Identification of recurrent FGFR3-TACC3 fusion oncogenes from lung adenocarcinoma","volume":"20","author":"Capelletti","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1200\/JCO.2013.50.8556","article-title":"Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients","volume":"32","author":"Kim","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.gore.2015.06.005","article-title":"FGFR3-TACC3: A novel gene fusion in cervical cancer","volume":"13","author":"Carneiro","year":"2015","journal-title":"Gynecol. Oncol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.cytogfr.2015.03.003","article-title":"Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations","volume":"26","author":"Gallo","year":"2015","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1002\/cncr.29826","article-title":"Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations","volume":"122","author":"Ross","year":"2016","journal-title":"Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"de Luca, A., Esposito Abate, R., Rachiglio, A.M., Maiello, M.R., Esposito, C., Schettino, C., Izzo, F., Nasti, G., and Normanno, N. (2020). FGFR Fusions in Cancer: From Diagnostic Approaches to Therapeutic Intervention. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21186856"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40478-020-00898-6","article-title":"FGFR-gene family alterations in low-grade neuroepithelial tumors","volume":"8","author":"Bale","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/ng.2611","article-title":"Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas","volume":"45","author":"Zhang","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40478-021-01170-1","article-title":"Novel targetable FGFR2 and FGFR3 alterations in glioblastoma associate with aggressive phenotype and distinct gene expression programs","volume":"9","author":"Georgescu","year":"2021","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1101\/gr.145144.112","article-title":"The transcriptional landscape and mutational profile of lung adenocarcinoma","volume":"22","author":"Seo","year":"2012","journal-title":"Genome Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jtho.2018.09.014","article-title":"Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic Profiling","volume":"14","author":"Qin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR Genetic Aberrations: A Unique Clinical Phenotype","volume":"2","author":"Jain","year":"2018","journal-title":"JCO Precis. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Churi, C.R., Shroff, R., Wang, Y., Rashid, A., Kang, H.C., Weatherly, J., Zuo, M., Zinner, R., Hong, D., and Meric-Bernstam, F. (2014). Mutation profiling in cholangiocarcinoma: Prognostic and therapeutic implications. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0115383"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/jnen\/nly022","article-title":"Targetable Gene Fusions Associate with the IDH Wild-Type Astrocytic Lineage in Adult Gliomas","volume":"77","author":"Ferguson","year":"2018","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1038\/onc.2014.406","article-title":"The landscape and therapeutic relevance of cancer-associated transcript fusions","volume":"34","author":"Yoshihara","year":"2015","journal-title":"Oncogene"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s40478-020-01058-6","article-title":"Genetic and epigenetic landscape of IDH-wildtype glioblastomas with FGFR3-TACC3 fusions","volume":"8","author":"Mata","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1158\/1535-7163.MCT-14-0927-T","article-title":"Mechanism of Oncogenic Signal Activation by the Novel Fusion Kinase FGFR3-BAIAP2L1","volume":"14","author":"Nakanishi","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1093\/annonc\/11.suppl_1.S131","article-title":"Recurrent immunoglobulin gene translocations identify distinct molecular subtypes of myeloma","volume":"11","author":"Chesi","year":"2000","journal-title":"Ann. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1016\/j.dnarep.2006.05.012","article-title":"Distinguishing primary and secondary translocations in multiple myeloma","volume":"5","author":"Gabrea","year":"2006","journal-title":"DNA Repair"},{"key":"ref_64","first-page":"475","article-title":"FGFR-TACC gene fusions in human glioma","volume":"19","author":"Lasorella","year":"2017","journal-title":"Neuro-oncology"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Still, I.H., Vettaikkorumakankauv, A.K., DiMatteo, A., and Liang, P. (2004). Structure-function evolution of the transforming acidic coiled coil genes revealed by analysis of phylogenetically diverse organisms. BMC Evol. Biol., 4.","DOI":"10.1186\/1471-2148-4-16"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"14352","DOI":"10.1073\/pnas.97.26.14352","article-title":"The TACC domain identifies a family of centrosomal proteins that can interact with microtubules","volume":"97","author":"Gergely","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1158\/1541-7786.MCR-15-0497","article-title":"Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation","volume":"14","author":"Nelson","year":"2016","journal-title":"Mol. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"34306","DOI":"10.18632\/oncotarget.26142","article-title":"Oncogenic driver FGFR3-TACC3 is dependent on membrane trafficking and ERK signaling","volume":"9","author":"Nelson","year":"2018","journal-title":"Oncotarget"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1093\/jnen\/nlx042","article-title":"Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System","volume":"76","author":"Ryall","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1007\/s00401-018-1882-3","article-title":"FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma","volume":"136","author":"Sievers","year":"2018","journal-title":"Acta Neuropathol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1093\/neuonc\/noaa296","article-title":"High frequency of disease progression in pediatric spinal cord low-grade glioma (LGG): Management strategies and results from the German LGG study group","volume":"23","author":"Perwein","year":"2021","journal-title":"Neuro-oncology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1093\/jnen\/nlaa122","article-title":"Spinal Cord Pilocytic Astrocytoma with FGFR1-TACC1 Fusion and Anaplastic Transformation","volume":"80","author":"Daoud","year":"2021","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"434","DOI":"10.21037\/jss-21-24","article-title":"FGFR1-TACC1 fusion associated with malignant transformation in a primary spinal cord glioma: A case report","volume":"7","author":"Asuzu","year":"2021","journal-title":"J. Spine Surg."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00401-016-1639-9","article-title":"Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): An epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway","volume":"133","author":"Huse","year":"2017","journal-title":"Acta Neuropathol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41698-017-0036-8","article-title":"Identification and targeting of an FGFR fusion in a pediatric thalamic \u201ccentral oligodendroglioma\u201d","volume":"1","author":"Linzey","year":"2017","journal-title":"NPJ Precis. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1158\/1078-0432.CCR-14-2199","article-title":"Detection, Characterization, and Inhibition of FGFR-TACC Fusions in IDH Wild-type Glioma","volume":"21","author":"Fucci","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/s11060-019-03114-1","article-title":"Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: A single institutional experience of 135 cases","volume":"142","author":"Na","year":"2019","journal-title":"J. Neurooncol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"CNS37","DOI":"10.2217\/cns-2019-0003","article-title":"Comparative proteogenomic characterization of glioblastoma","volume":"8","author":"Asif","year":"2019","journal-title":"CNS Oncol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1101\/gr.165126.113","article-title":"RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas","volume":"24","author":"Bao","year":"2014","journal-title":"Genome Res."},{"key":"ref_80","first-page":"209","article-title":"FGFR3 overexpression is a useful detection tool for FGFR3 fusions and sequence variations in glioma","volume":"8","author":"Schittenhelm","year":"2021","journal-title":"Neurooncol. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1093\/neuonc\/noaa121","article-title":"Clinical, molecular, and radiomic profile of gliomas with FGFR3-TACC3 fusions","volume":"22","author":"Picca","year":"2020","journal-title":"Neuro-oncology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1126\/science.1117679","article-title":"Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer","volume":"310","author":"Tomlins","year":"2005","journal-title":"Science"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Kurobe, M., Kojima, T., Nishimura, K., Kandori, S., Kawahara, T., Yoshino, T., Ueno, S., Iizumi, Y., Mitsuzuka, K., and Arai, Y. (2016). Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE Samples. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0165109"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/bpa.12563","article-title":"Diffuse gliomas with FGFR3-TACC3 fusion have characteristic histopathological and molecular features","volume":"28","author":"Bielle","year":"2018","journal-title":"Brain Pathol."},{"key":"ref_85","first-page":"1206","article-title":"Strong FGFR3 staining is a marker for FGFR3 fusions in diffuse gliomas","volume":"19","author":"Granberg","year":"2017","journal-title":"Neuro-oncology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"823015","DOI":"10.3389\/fneur.2022.823015","article-title":"Glioblastoma, IDH-Wild Type with FGFR3-TACC3 Fusion: When Morphology May Reliably Predict the Molecular Profile of a Tumor. A Case Report and Literature Review","volume":"13","author":"Broggi","year":"2022","journal-title":"Front. Neurol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.5414\/NP301357","article-title":"Can adult IDH-wildtype glioblastomas with FGFR3:TACC3 fusions be reliably predicted by histological features?","volume":"40","author":"Gilani","year":"2021","journal-title":"Clin. Neuropathol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00401-022-02430-7","article-title":"DNA methylation analysis of glioblastomas harboring FGFR3-TACC3 fusions identifies a methylation subclass with better patient survival","volume":"144","author":"Wu","year":"2022","journal-title":"Acta Neuropathol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40644-022-00455-5","article-title":"Imaging diagnosis and treatment selection for brain tumors in the era of molecular therapeutics","volume":"22","author":"Vagvala","year":"2022","journal-title":"Cancer Imaging"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature25171","article-title":"A metabolic function of FGFR3-TACC3 gene fusions in cancer","volume":"553","author":"Frattini","year":"2018","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/onc.2016.216","article-title":"FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR\/ERK signaling","volume":"36","author":"Daly","year":"2017","journal-title":"Oncogene"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"102898","DOI":"10.18632\/oncotarget.22048","article-title":"Unique signalling connectivity of FGFR3-TACC3 oncoprotein revealed by quantitative phosphoproteomics and differential network analysis","volume":"8","author":"Lombardi","year":"2017","journal-title":"Oncotarget"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.bjc.6606016","article-title":"Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo","volume":"104","author":"Lamont","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.canlet.2016.05.017","article-title":"Antitumor effect of FGFR inhibitors on a novel cholangiocarcinoma patient derived xenograft mouse model endogenously expressing an FGFR2-CCDC6 fusion protein","volume":"380","author":"Wang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.4161\/15384047.2014.961874","article-title":"Recurrent FGFR3-TACC3 fusion gene in nasopharyngeal carcinoma","volume":"15","author":"Yuan","year":"2014","journal-title":"Cancer Biol. Ther."},{"key":"ref_96","first-page":"vdaa132","article-title":"RNAi technology targeting the FGFR3-TACC3 fusion breakpoint: An opportunity for precision medicine","volume":"2","author":"Ledbetter","year":"2020","journal-title":"Neurooncol. Adv."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/onco.13530","article-title":"Targeted Therapy with Anlotinib for a Patient with an Oncogenic FGFR3-TACC3 Fusion and Recurrent Glioblastoma","volume":"26","author":"Wang","year":"2021","journal-title":"Oncologist"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"3401","DOI":"10.1200\/JCO.2014.60.7341","article-title":"Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced Solid Tumors","volume":"33","author":"Tabernero","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1158\/1078-0432.CCR-21-2664","article-title":"Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study","volume":"28","author":"Lassman","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8675\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:04:04Z","timestamp":1760141044000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/15\/8675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,4]]},"references-count":99,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["ijms23158675"],"URL":"https:\/\/doi.org\/10.3390\/ijms23158675","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,4]]}}}